Plasma high density lipoprotein (HDL) levels are strongly genetically determined and show a general inverse relationship with coronary heart disease (CHD). The cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl esters from HDL to other lipoproteins and is a key participant in the reverse transport of cholesterol from the periphery to the liver. A high prevalence of two different CETP gene mutations (D442G, 5.1%; intron 14G:A, 0.5%), was found in 3,469 men of Japanese ancestry in the Honolulu Heart Program and mutations were associated with decreased CETP (-35%) and increased HDL chol levels (+10% for D442G). However, the overall prevalence of definite CHD was 21% in men with mutations and 16% in men without mutations. The relative risk (RR) of CHD was 1.43 in men with mutations (P < .05); after adjustment for CHD risk factors, the RR was 1.55 (P = .02); after additional adjustment for HDL levels, the RR was 1.68 (P = .008). Similar RR values were obtained for the D442G mutation alone. Increased CHD in men with mutations was primarily observed for HDL chol 41-60 mg/dl; for HDL chol > 60 mg/dl men with and without mutations had low CHD prevalence. Thus, genetic CETP deficiency appears to be an independent risk factor for CHD, primarily due to increased CHD prevalence in men with the D442G mutation and HDL cholesterol between 41 and 60 mg/dl. The findings suggest that both HDL concentration and the dynamics of cholesterol transport through HDL (i.e., reverse cholesterol transport) determine the anti-atherogenicity of the HDL fraction.
S Zhong, D S Sharp, J S Grove, C Bruce, K Yano, J D Curb, A R Tall
Title and authors | Publication | Year |
---|---|---|
ABC transporters, atherosclerosis and inflammation
ML Fitzgerald, Z Mujawar, N Tamehiro |
Atherosclerosis | 2010 |
Streptococcal Serum Opacity Factor Increases the Rate of Hepatocyte Uptake of Human Plasma High-Density Lipoprotein Cholesterol
BK Gillard, C Rosales, BK Pillai, HY Lin, HS Courtney, HJ Pownall |
Biochemistry | 2010 |
Cholesteryl Ester Transfer Protein and Mortality in Patients Undergoing Coronary Angiography: The Ludwigshafen Risk and Cardiovascular Health Study
A Ritsch, H Scharnagl, P Eller, I Tancevski, K Duwensee, E Demetz, A Sandhofer, BO Boehm, BR Winkelmann, JR Patsch, W März |
Circulation | 2010 |
Burger's Medicinal Chemistry and Drug Discovery
S Bruno, L Ronda, S Faggiano, S Bettati, A Mozzarelli |
Burger's Medicinal Chemistry and Drug Discovery | 2010 |
Cholesteryl ester transfer protein and its inhibition
O Weber, H Bischoff, C Schmeck, MF Böttcher |
Cellular and Molecular Life Sciences | 2010 |
High-Density Lipoprotein and Coronary Heart Disease
P Natarajan, KK Ray, CP Cannon |
Journal of the American College of Cardiology | 2010 |
Atherosclerosis regression and high-density lipoproteins
JM Lee, RP Choudhury |
Expert Review of Cardiovascular Therapy | 2010 |
Anacetrapib: Hope for CETP Inhibitors?
R Gurfinkel, TR Joy |
Cardiovascular Therapeutics | 2010 |
Mulling over the odds of CETP inhibition
A Eckardstein |
European Heart Journal | 2010 |
Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target?
A Eckardstein |
Expert Review of Cardiovascular Therapy | 2010 |
Interaction between diets, polymorphisms and plasma lipid levels
I Rudkowska, MC Vohl |
Clinical Lipidology | 2010 |
High-density lipoprotein therapeutics and cardiovascular prevention
S Fazio, MR Linton |
Journal of Clinical Lipidology | 2010 |
Cholesteryl Ester Transfer Protein Taq1B Polymorphism in an Angiographically Assessed Turkish Population: No Effects on Coronary Artery Disease Risk
S Tanrikulu-Kucuk, E Ademoglu, F Gurdol, AK Bilge, U Mutlu-Turkoglu, Y Nisanci |
Genetic Testing and Molecular Biomarkers | 2010 |
Cholesteryl ester transfer protein gene polymorphisms and longevity syndrome
G Kolovou, M Stamatelatou, K Anagnostopoulou, P Kostakou, V Kolovou, C Mihas, I Vasiliadis, O Diakoumakou, DP Mikhailidis, DV Cokkinos |
The open cardiovascular medicine journal | 2010 |
Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors
A Wang, CP Prouty, PD Pelton, M Yong, KT Demarest, WV Murray, GH Kuo |
Bioorganic & Medicinal Chemistry Letters | 2010 |
Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population
R Frikke-Schmidt |
Atherosclerosis | 2010 |
High Density Lipoprotein (HDL) Modulation Targets
SS Mousa, RC Block, SA Mousa |
Drugs of the future | 2010 |
The HDL Handbook
NJ Hime |
The HDL Handbook | 2010 |
Formes rares de dyslipidémies génétiques
G Luc |
EMC - Endocrinologie - Nutrition | 2010 |
Les dyslipidémies héréditaires
P Couvert, P Giral, D Bonnefont-Rousselot, A Carrié |
Revue Francophone des Laboratoires | 2010 |
Dalcetrapib: a review of Phase II data
JG Robinson |
Expert Opinion on Investigational Drugs | 2010 |
Biochemical characterization of cholesteryl ester transfer protein inhibitors
M Ranalletta, KK Bierilo, Y Chen, D Milot, Q Chen, E Tung, C Houde, NH Elowe, M Garcia-Calvo, G Porter, S Eveland, B Frantz-Wattley, M Kavana, G Addona, P Sinclair, C Sparrow, EA O'Neill, KS Koblan, A Sitlani, B Hubbard, TS Fisher |
Journal of lipid research | 2010 |
Vegetables, Whole Grains, and Their Derivatives in Cancer Prevention
M Mutanen, AM Pajari |
2010 |